Withdrawal Treatments for Narcotic Addictions — NCD 59 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 59, the national coverage determination governing withdrawal treatments for narcotic addiction, effective January 9, 2026. Here's what billing teams need to know before submitting Part B claims for these services.

CMS narcotic addiction withdrawal treatment coverage policy falls under NCD 59 in the Medicare system. This modification clarifies Part B coverage for physician-directed withdrawal services and the drugs provided in connection with that treatment. No specific CPT or HCPCS codes are listed in the policy document — a gap your billing team needs to work around carefully.

Quick-Reference Table

CMS Narcotic Addiction Withdrawal Treatment Coverage Criteria and Medical Necessity Requirements 2026

NCD 59 is the National Coverage Determination that governs whether Medicare Part B pays for withdrawal treatment for narcotic addiction. The coverage policy has a narrow but clear structure. Get the basics wrong and you'll see claim denial before you can trace the problem.

CMS covers withdrawal treatment when the physician provides the service directly or under personal supervision. "Personal supervision" under Medicare rules means the physician is present in the office suite and immediately available — not simply available by phone. That distinction matters for every claim you submit under this policy.

Medical necessity is not self-certified here. Your Medicare Administrative Contractor (MAC) determines reasonableness and necessity using their own medical staff. This is a MAC-level review process, which means coverage decisions can vary by region. What passes scrutiny in one jurisdiction may not pass in another.

The CMS narcotic addiction withdrawal treatment coverage policy also extends to drugs the physician provides during treatment. Those drugs are covered under Part B when two conditions are both met: the drug cannot be self-administered, and it meets all other statutory requirements for Medicare drug coverage. Both conditions must apply. One without the other is not enough for reimbursement.

This is where the policy gets tricky for billing teams. "Cannot be self-administered" is a well-established Medicare standard, but applying it correctly to specific addiction treatment drugs requires clinical documentation and billing judgment. If your clinical team is administering a drug that a patient could theoretically self-administer, that drug is not billable under this pathway — even if the physician is present.

The effective date of January 9, 2026 applies to the modified policy. Review any claims submitted after that date against the updated criteria.

There is no prior authorization requirement listed in NCD 59. However, given that your MAC's medical staff reviews these claims for medical necessity, treat your documentation like it's going through prior authorization-level scrutiny. The threshold is the same even if the process is post-submission.

Cross-reference this policy against Chapter 6, Section 20.4.1 of the Medicare Benefit Policy Manual for the hospital services angle. If your team also bills withdrawal services in an outpatient hospital setting, that chapter is your secondary reference.

Coverage Indications at a Glance

CMS Narcotic Addiction Withdrawal Treatment Billing Guidelines and Action Items 2026

Narcotic addiction withdrawal billing under NCD 59 has real exposure points. Here's how to address them directly.

CPT, HCPCS, and ICD-10 Codes for Narcotic Addiction Withdrawal Treatment Under NCD 59

Covered CPT Codes (When Selection Criteria Are Met)

This policy does not list specific CPT or HCPCS codes. CMS has not assigned a defined code set to NCD 59 in this version of the policy.

This is a real problem for billing teams. Without explicit code guidance, you're working from clinical documentation and general E/M billing rules to determine the right codes. Your MAC's claims processing instructions are the next place to look. Contact your MAC directly to confirm which procedure codes they expect on claims for physician-directed narcotic withdrawal services.

Not Covered / Experimental Codes

No specific codes are designated as non-covered or experimental in this policy document.

Key ICD-10-CM Diagnosis Codes

No ICD-10-CM codes are listed in NCD 59 as published. For diagnosis coding, your billing team should use the appropriate opioid dependence and withdrawal codes from the ICD-10-CM manual. Confirm with your MAC that your diagnosis code selection aligns with their medical necessity review criteria for this service category.

What the Absence of Specific Codes Really Means for Your Team

The lack of explicit procedure codes in NCD 59 is the biggest operational challenge this policy creates. It's not unusual for older NCD policies to lack code-level specificity — CMS sometimes issues coverage determinations that predate the current CPT code structure. But it puts your billing team in a difficult position.

You have a coverage policy with real criteria and real exposure. You don't have a code table to anchor your charge capture to. That gap is where claim denial risk lives.

The practical answer is a two-step process. First, identify which E/M codes or procedure codes your physicians currently use for these services. Second, validate those codes with your MAC before the January 9, 2026 effective date passes and claims start going out under the modified policy. Don't assume the codes you've been using are still the right ones without that confirmation.

If your practice bills a meaningful volume of narcotic addiction withdrawal services, this conversation with your MAC — and your compliance officer — is not something to defer.